Collective evidence indicates that motor neuron degeneration in amyotrophic lateral sclerosis (ALS) is noncell-autonomous and requires the interaction with the neighboring astrocytes. Recently, we reported that a subpopulation of spinal cord astrocytes degenerates in the microenvironment of motor neurons in the hSOD1 G93A mouse model of ALS. Mechanistic studies in vitro identified a role for the excitatory amino acid glutamate in the gliodegenerative process via the activation of its inositol 1,4,5-triphosphate (IP 3 )-generating metabotropic receptor 5 (mGluR5 Rs with the anti-apoptotic protein Bcl-X L was previously described to prevent cell death by modulating intracellular Ca 21 signals. In mutant SOD1-expressing astrocytes, we found that the sole BH4 domain of Bcl-X L , fused to the protein transduction domain of the HIV-1 TAT protein (TAT-BH4), is sufficient to restore sustained Ca 21 oscillations and cell death resistance. Furthermore, chronic treatment of hSOD1 G93A mice with the TAT-BH4 peptide reduces focal degeneration of astrocytes, slightly delays the onset of the disease and improves both motor performance and animal lifespan. Our results point at TAT-BH4 as a novel glioprotective agent with a therapeutic potential for ALS.
INTRODUCTION
In the adult nervous system, the major glial cell type is represented by the astrocytes. These cells fulfill several homeostatic functions that collectively contribute to maintain the optimal microenvironment for neuronal function and survival (1, 2) . In addition, astrocytes can sense neuronal activity by a large repertoire of neurotransmitter receptors located in their plasma membrane (3) and, in turn, they can respond to neurons by Ca 2+ -dependent release of gliotransmitters (4, 5) . The multiplicity and complexity of these activities clearly indicate that the correct performance of the astrocytes is crucial for the physiological functioning of the nervous system and its derangement may affect neuronal activity and contribute to neurodegeneration.
A growing number of recent observations suggests that, in amyotrophic lateral sclerosis (ALS), a complex pathological interplay subsists between motor neurons and the neighboring † These authors contributed equally to this work. ‡ Present address: Institute of Neuropathology, Schmelzbergstrasse 12, 8091 Zurich, Switzerland. * To whom correspondence should be addressed at: Laboratory for Research on Neurodegenerative Disorders, IRCCS Fondazione Salvatore Maugeri, Via Maugeri 10, 27100 Pavia, Italy. Tel: +39 0382592064; Fax: +39 0382592094; Email: daniela.rossi@fsm.it glial cells, particularly astrocytes (6 -12) . Astroglial cells were described to cause damage to motor neurons directly by releasing toxic factors, but also indirectly via the loss of their physiological functions (10, 11, (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) . Within this framework, we and others reported that a subset of astrocytes, positioned in the microenvironment of motor neurons, undergoes degeneration in the spinal cord of transgenic mice overexpressing the G93A form of mutant human superoxide dismutase 1 (hSOD1 G93A ) (24, 25) . This phenomenon occurs prior to symptom onset and is mediated by the excitatory amino acid glutamate via the activation of its inositol 1,4,5-triphosphate (IP 3 )-producing metabotropic receptor type-5 (mGluR5) (25) . The physiological production of IP 3 under the stimulation of cell-surface receptors, such as mGluR5, normally triggers the release of Ca 2+ from the endoplasmic reticulum (ER) by opening the IP 3 receptor (IP 3 R) channels. Such Ca 2+ plays a role in modulating a variety of cellular responses that are fundamental for cell function and survival (26) . However, Ca 2+ released under nonphysiological conditions can activate different pathways of cell death (27 -31) . Importantly, the anti-apoptotic Bcl-2 family members, particularly Bcl-2 and Bcl-X L , were reported to confer cell death protection by altering the Ca 2+ permeability of the IP 3 R channels (29,31 -38) . The anti-apoptotic activity of these proteins has been mostly ascribed to their homology domain 4 (BH4), and the one from Bcl-X L appears to be more efficient than that of Bcl-2 (39 -41) .
As a protective role for the Bcl-2 family proteins has been clearly identified in the mechanisms of cell death triggered by ALS-linked mutant SOD1s (42) (43) (44) (45) (46) (47) (48) , here we tested the impact on astrocyte physiology and survival of a biologically active peptide consisting of the BH4 domain of Bcl-X L fused to the protein transduction domain of the human immunodeficiency virus (HIV) TAT protein (TAT-BH4). We report that although mGluR5-driven degeneration of ALS astrocytes is coupled to aberrant intracellular Ca 2+ handling, the treatment with TAT-BH4 affords cell death resistance by enhancing prosurvival Ca 2+ oscillations. Furthermore, chronic administration of TAT-BH4 in vivo, to hSOD1 G93A transgenic mice, reduces degeneration of spinal cord astrocytes, slightly postpones the appearance of ALS symptoms and improves both motor performance and survival.
RESULTS

Aberrant expression of mGluR5 in ALS tissues
A degenerative process of the astrocytes that spatially and temporally correlates with the progression of ALS disease was previously identified in the spinal cord of hSOD1 G93A mice (25) . Degenerating astroglial cells were morphologically characterized by an unusually thick and spheroidal cap of glial fibrillary acidic protein (GFAP) (Fig. 1A, hSOD1 G93A , 100 days), which was associated with rare GFAP-positive processes and resulted immunopositive for the active caspase-3 (25) . Neuropathological analyses of autoptic tissues from patients affected by sporadic ALS confirmed that these unusual GFAP-and active caspase-3-positive cellular profiles are present in the neighborhood of motor neurons also in the ventral horns of the spinal cord from sALS cases (Fig. 1B and Supplementary Material, Fig. S1 ). Because a role for mGluR5 was originally identified in the gliodegenerative process in vitro (25) , we next investigated the expression of the receptor messenger RNA (mRNA) in vivo, in the spinal cord of hSOD1 G93A ALS mice and wild-type control animals, at different ages during disease progression. Quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis revealed that, in wild-type mice, mGluR5 mRNA levels remain fairly constant throughout life (Supplementary Material, Fig. S2A ). In contrast, at the presymptomatic age of 30 days, the transcripts of the receptor result up-regulated in hSOD1 G93A mice when compared with age-matched wild-type animals. Yet, their levels significantly decrease at the time of disease onset, i.e. about 100 days of age, when the degree of expression becomes comparable with that in wild-type mice (Supplementary Material, Fig. S2A ).
The expression and cellular distribution of the mGluR5 protein was subsequently explored in situ in mGluR5-immunolabeled spinal cord sections from hSOD1 G93A and wild-type animals. In both instances, we found that mGluR5 shows the typical punctuate staining of receptor clusters throughout lumbar spinal cord sections, in both neuronal as well as glial cells (Fig. 1A and Supplementary Material, Fig. S2B ). However, quantitative analysis of mGluR5-immunofluorescent puncta confirmed a generally enhanced expression of the receptor in 30-day-old hSOD1 G93A mice when compared with wild-type animals (Supplementary Material, Fig. S2C ). Because at this phase of the disease, the degree of expression of the astrocytic and microglial markers, GFAP and CD11b, was similar in the two genotypes (GFAP or CD11b expression levels in wild-type mouse spinal cord were set as 100%; expression levels in 30-day-old hSOD1 G93A mouse spinal cord: GFAP: 75 + 13% versus wildtype, P ¼ 0.27, unpaired t-test; CD11b: 102 + 15% versus wild-type, P ¼ 0.12, unpaired t-test, n ¼ 6 fields from three mice), we infer that the increase in mGluR5 levels is independent on hyperproliferation of reactive glia. Rather, it is a consequence of the presence of mutant SOD1 in the different cell types. Interestingly, immunohistochemical analyses of hSOD1 G93A spinal cords, taken at the time of disease onset, confirmed that the expression of mGluR5 was quantitatively comparable with wild-type spinal cords, but significantly lower than that in 30-day-old ALS mice (Supplementary Material, Fig. S2C ). This decrease in the amount of mGluR5 cannot be fully ascribed to motor neuron loss (Fig. 7E) , as we observed a substantial reduction in the expression of the receptor (227.8 + 2.3%, n ¼ 9 fields from three mice) also in regions of the spinal cord where the motor cells are still alive. Noteworthy, at this stage of the disease, degenerating astrocytes were largely represented and maintained a stronger immunoreactivity for mGluR5 when compared with the neighboring cells. This profile was determined by enhanced and closely adjacent mGluR5-positive puncta (Fig. 1A,  hSOD1 G93A , 100 days). In keeping with these observations, we found a similar pattern of mGluR5 expression also in autoptic sALS spinal cords (Fig. 1B) . The fact that mGluR5 is over-expressed in the spinal cord of hSOD1 G93A mice at the pre-symptomatic stage of the disease, but not at the time of disease onset strongly suggests that this receptor plays a ] i increase in mutant SOD1-expressing cells (Fig. 2D) (53) .
Similarly, application of xestospongin C (XeC, 1 mM), a specific inhibitor of the IP 3 receptors (54), reduced the amplitude of the initial peak to about 20% of the control level and significantly decreased the following persistent rise in cytosolic Ca 2+ (285% of DF/F 0 with respect to hSOD1 G93A cells, Fig. 2D Fig. 2D ) in several minutes. Remarkably, no significant differences were found between the conditions with and without extracellular calcium (Fig. 2D ). This suggests that the DHPG-mediated [Ca 2+ ] i plateau observed in hSOD1 G93A spinal cord astrocytes is not due to the influx of extracellular Ca 2+ , but it is mostly caused by the activation of the IP 3 receptors and the release of Ca 2+ from the internal stores.
Considerable evidence suggests that the function of the ER is intimately connected with that of mitochondria. Thus, during normal signaling, there is a continuous flow of Ca 2+ between the two organelles, which is relevant for the mitochondrial metabolic activity. However, alterations in Ca 2+ homeostatic mechanisms that result in massive and/or prolonged mitochondrial [Ca 2+ ] i overload can cause the release of cytochrome c, located between the inner and the outer mitochondrial membranes. This event can lead to the activation of cell death effector caspases (30, 31) . On the basis of these considerations, we postulated that the unusual efflux of intracellular Ca 2+ detected in the mutant SOD1-expressing cells, in combination with the loss of IP 3 R-dependent [Ca 2+ ] i oscillations, may underlie degeneration of ALS astrocytes (31) . In agreement with this hypothesis, we confirmed that the same concentration of DHPG triggers the release of cytochrome c from mitochondria (Fig. 5A ). This event is associated with delayed (24 h) caspase-3 activation and nuclear condensation in a subset of mutant SOD1-expressing astrocytes (Fig. 5B ). Because mGluR5, but not the closely related mGluR1 (55) , is expressed in cultured astrocytes, we conclude that the effects elicited by DHPG in ALS astroglial cells can be ascribed to mGluR5 activation. ] i oscillations, an event that has been correlated with increased cell death resistance (36, 37) . On the basis of this, we next investigated the expression of Bcl-X L in cultured astrocytes by immunocytochemistry. Immunofluorescence quantification revealed that the levels of Bcl-X L were significantly reduced to 78% in astrocytes harboring mutant SOD1 when compared with wild-type cells (Fig. 3) . As the BH4 domain of Bcl-X L importantly contributes to cell death suppression (35, (39) (40) (41) , we then examined whether a fusion peptide, in which BH4 is conjugated with the cell-penetrating TAT peptide from the HIV-1 virus (TAT-BH4, Supplementary Material, Fig. S4A ) (56) , was transduced into primary astrocytes, and we studied its stability inside the cells over time. Astroglial cells in culture were thus incubated with either unconjugated or 5(6)-carboxyfluorescein (FAM)-conjugated TAT-BH4 (TAT-BH4-FAM, 0.5 mM, 30 min, Supplementary Material, Fig. S4B ). Cells were subsequently washed and either immediately fixed or maintained in culture for 24 h and then fixed, according to the timing of our toxicity experiments (25) . The presence of TAT-BH4-FAM into nearly 100% of astrocytes was confirmed by fluorescence microscopy. Furthermore, significant levels of the transduced fluorescent marker persisted in the astrocytes even 24 h after the removal of the peptide from the cell culture media (Supplementary Material, Fig. S4B ). Noteworthy, analysis of intracellular BH4 levels, using an antibody that reacts with both the endogenous full-length Bcl-X L protein and the internalized TAT-BH4 peptide (57) , revealed that the treatment with TAT-BH4 restored 94% of Bcl-X L BH4 levels in mutant SOD1-expressing astrocytes (Fig. 3) .
The efficacy of TAT-BH4 in regulating the [Ca 2+ ] i signaling was then tested in the mutant cells. Calcium imaging experiments were first carried out by challenging Fluo4-loaded wild-type and hSOD1
G93A -expressing astrocytes with TAT-BH4 (0.5 mM, 30 min). To our surprise, we found that the local application of TAT-conjugated BH4 caused an immediate [Ca 2+ ] i rise and restored sustained [Ca 2+ ] i oscillations in hSOD1 G93A -expressing astrocytes (Fig. 4A ). These oscillations were strongly inhibited in the presence of agents that either deplete the intracellular Ca 2+ stores (TG, 294.5 + 3.9% of oscillatory responding cells; n ¼ 50 cells analyzed; n ¼ 8 experiments) or inhibit the IP 3 Rs (XeC, 292.5 + ] i signaling by modulating the IP 3 R activity. Administration of the group I mGluR agonist DHPG (100 mM), 30 min after the application of TAT-BH4, triggered the typical single [Ca 2+ ] i transient in 99% of the cells, followed by persistent [Ca 2+ ] i oscillations ( Fig. 4A and B) . The average oscillation frequency was similar to that of wild-type cells ( Fig. 4A and D) , and these effects were fully dependent on the release of Ca 2+ from the internal stores, as determined by pharmacological experiments (Fig. 4B and C G93A -expressing astrocytes correlated with a glioprotective effect of TAT-BH4 against mGluR5-dependent excitotoxic damage. Spinal astrocytic cultures from hSOD1 G93A or wild-type mice were pre-incubated in the absence or presence of 0.5 mM TAT-BH4 for 30 min. The peptide in excess was then removed and cells were exposed to 100 mM DHPG or control solution (30 min). In the absence of TAT-BH4, we confirmed that DHPG induces the release of cytochrome c from mitochondria (Fig. 5A) , an event that is associated to caspase-3 activation and nuclear condensation selectively in mutant SOD1-expressing astrocytes (Fig. 5B) (25) . However, when astrocytes deriving from hSOD1 G93A mice were pretreated with the TAT-BH4 peptide, we detected a significant reduction in both the release of cytochrome c and the apoptotic parameters ( Fig. 5A and B) . To ascertain whether the identified alterations in intracellular Ca 2+ signaling strictly ] i imaging of wild-type astrocytes stimulated with staurosporine (STS), a well-established pro-apoptotic stimulus that leads to cell death by causing IP 3 R-dependent Ca 2+ leak from the intracellular stores via the activation of IP 3 Rs (38,58-61). Similar to DHPG-stimulated ALS astrocytes, we found that STS (1 mM) triggers a persistent increase in cytosolic calcium that reaches the plateau in about 75-80 min. This event is coupled to the absence of evident calcium oscillations (Fig. 6A) . However, when STS was administered 30 min after the application of TAT-BH4, a significant reduction in the levels of intracellular calcium (272% with respect to cells treated with STS alone), coupled to the re-establishment of [Ca 2+ ] i oscillations, was observed (Fig. 6B) . Interestingly, the variations in [Ca 2+ ] i occurring in the absence or presence of TAT-BH4 quantitatively correlated with astrocyte degeneration. Indeed, in parallel experiments, we found that treating astrocytes with STS (1 mM) in the absence of the peptide caused cell death, as determined by nuclear condensation (Fig. 6C) . When cells were pre-incubated with increasing concentrations of TAT-BH4 (0.1 and 0.5 mM, 30 min), however, astrocyte degeneration was potently inhibited in a dose-dependent fashion (Fig. 6C) . In view of the impact of STS on IP3Rs, we conclude that astroglial transduction of TAT-BH4 is effective in protecting the cells against IP 3-R-driven cell death.
In vivo administration of TAT-BH4 reduces astrocyte degeneration, slightly postpones disease onset and improves both motor performance and survival of hSOD1 G93A mice
On the basis of the above observations, we next decided to assess the therapeutic potential of TAT-BH4 in vivo on ALS transgenic mice. Starting at the age of 40 days, hSOD1 G93A animals were treated daily with TAT-BH4 (5 mg/kg intraperitoneally) or equivalent volumes of vehicle solution (saline). Thereafter, mice were monitored daily for survival and twice a week for both decline in body weight and motor performance, using the rotarod test. As weight gain stops at the time of disease onset, the peak in the body weight curve was taken as the earliest measure of the onset of the disease (8, 9) . According to this criterion, we found that the disease manifestation was slightly, but significantly, delayed in mice injected with TAT-BH4 compared with controls (saline: 99.1 + 2.9 days; TAT-BH4: 107.5 + 1.8 days, n ¼ 14 per experimental group; P , 0.05, Logrank test; Fig. 7A ). In addition, animals treated with the peptide performed significantly better in the rotarod tasks throughout life ( Fig. 7B ) and had a prolonged survival time compared with vehicle-injected mice (saline: 123 + 2.1 days; TAT-BH4: 138 + 2.1 days, n ¼ 14 per experimental group; P , 0.001, Logrank test; Fig. 7C) . Immunohistochemical analyses were then performed on spinal cords from a cohort of mice sacrificed at about 100 days of age, i.e. the time of disease onset. Transduction of the peptide was first evaluated at the cellular levels by double immunostaining using antibodies for TAT and the astrocyte-and neuron-specific markers GFAP and microtubule-associated proteins (MAPs), respectively. Although robust immunoreactivity was detected in most astrocytes, motor neurons showed rather heterogeneous staining, with some cells displaying a faint immunosignal (Supplementary Material, Fig. S4C ). The expression of mGluR5 was then analyzed on spinal cord sections from both control and peptide-treated hSOD1 G93A mice double stained for the receptor and GFAP or the neuronal non-phosphorylated neurofilament marker (SMI32). Quantification of mGluR5 immunofluorescence in astrocytes and motor neurons revealed that the expression and distribution of the receptor was unchanged upon treatment with TAT-BH4 in both cell types (mGluR5 expression levels in astrocytes or motor neurons from control hSOD1 G93A mice was set as 100%; mGluR5 expression levels in TAT-BH4-injected hSOD1 G93A mouse spinal cords: astrocytes: 97.4 + 3.1% versus saline, P ¼ 0.50, unpaired t-test; motor neurons: 96.5 + 2.4% versus saline, P ¼ 0.47, unpaired t-test, n ¼ 6 cells from three mice). To determine whether the positive effect of the peptide on disease onset and progression was related to the identified degenerative process of astrocytes, we next investigated the impact of TAT-BH4 on both glial and neuronal cells. We found that the treatment with the peptide significantly reduced the number of spheroid astrocytes immunopositive for the active caspase-3 located in the motor neuron microenvironment (274% with respect to saline-treated mice, G93A mice (n ¼ 3 mice for each condition). Data (mean + s.e.m.) are expressed as % of total motor neurons present in 30-day-old hSOD1 G93A mice (596.1 + 96.14; * P , 0.05 versus saline, one-way ANOVA followed by Bonferroni post-hoc test). ; n ¼ 18 fields from three mice; P , 0.05, unpaired t-test). This result correlated with the preservation of a greater number of motor neurons (Fig. 7E) . On the basis of these findings, we conclude that the treatment with TAT-BH4 slightly delays the onset of the disease, slows the rate of disease progression and reduces degeneration of astrocytes and motor neurons.
DISCUSSION
Considerable evidence indicates that degeneration of motor neurons in ALS is non-cell-autonomous and requires combined alterations in motor neurons and the surrounding nonneuronal cells, particularly astrocytes (6 -11,13-23) . In this context, we and others previously described a degenerative process of the astrocytes located in the neighborhood of motor neurons in the spinal cord of hSOD1 G93A transgenic mice (24, 25) . We postulated that astroglial loss may deprive the adjacent motor neurons of the optimal microenvironment and, thus, exacerbate their degeneration.
In this study, we further expanded this observation by analyzing post-mortem tissues from sporadic ALS patients. We found that gliodegeneration is not only a peculiarity of the hSOD1 G93A mouse model of familial ALS, but occurs also in the sporadic form of the disease, thus corroborating the relevance of this phenomenon in the context of the human pathology. Astrocyte death is not an unusual event in neurodegenerative disorders characterized by a neuroinflammatory response and may represent a self-protective mechanism to limit the intensity and duration of reactive gliosis (62, 63) . However, loss of specific subpopulations of astroglia or those cells located in strategic positions may compromise neuronal activity and survival by restraining their neurosupportive factors and functions (64) .
On a mechanistic standpoint, prior studies in vitro implied the involvement of mGluR5 in the process of astroglial damage (25) . In keeping with this, here we found that dying astrocytes are strongly immunoreactive for mGluR5 in the spinal cord of both symptomatic hSOD1 G93A mice and autoptic sALS cases, suggesting that this receptor may be involved in the gliodegenerative process also in vivo.
The stage at which mGluR5 becomes relevant for ALS progression was then investigated by determining the degree of the receptor expression in the spinal cord of hSOD1 G93A ALS mice. The overall levels of mGluR5 resulted significantly enhanced in young, pre-symptomatic ALS animals, thus indicating that the receptor is likely to play a major role during the early phases of the disease. Noteworthy, also neonatal astrocytic cultures, prepared from the spinal cord of hSOD1 G93A mice, displayed increased expression of mGluR5 transcripts, confirming that the up-regulation of mGluR5 occurs during the early development in ALS astroglia.
In normal astrocytes, the activation of group I mGluRs, including mGluR5, triggers the formation of IP 3 and the consequent release of Ca 2+ from the ER, resulting in intracellular calcium oscillations (49, 50) .
In general, Ca 2+ released from the intracellular stores is rapidly taken up by closely juxtaposed mitochondria. An increase in mitochondrial Ca 2+ then fine tunes the organelle function to the enhanced needs of the activated cells (31, 65) . However, non-physiological release of Ca 2+ from the ER, in response to IP 3 production, may result in mitochondrial Ca 2+ overload and, thus, recruit mitochondria to the apoptotic cascade (27) (28) (29) (30) (31) 38) . Consistent with this, here we found that stimulating hSOD1 G93A -expressing astrocytes with DHPG, a group I mGluR agonist, does not produce calcium spiking, but causes in about 99% of the cells a persistent [Ca 2+ ] i rise, which is exceptionally elevated in a number of cells. This event is fully dependent on the Ca 2+ efflux from the ER, suggesting that not only the expression of mGluR5 is altered in mutant SOD1 astrocytes, but also the function of its downstream signaling effectors. Misfolded mutant SOD1s were recently reported not to cause Ca 2+ handling defects in spinal cord mitochondria (24, 25, 66, 67) . However, we postulated that an increased release of ER Ca 2+ in ALS astrocytes may enhance mitochondrial Ca 2+ uptake and, thus, trigger astroglial cell death. In keeping with this, here we found that the abnormal rise in cytosolic calcium triggered by DHPG correlates with mitochondrial disarrangement, release of cytochrome c and degeneration of a fraction of ALS astrocytes. These results are fully consistent with a previous study describing reduced capacity of mitochondria from the spinal cord of mutant SOD1 mice to survive repetitive Ca 2+ challenge (68) . Furthermore, they are in agreement with a recent report describing mitochondrial dysfunction in mutant SOD1-expressing astrocytes (19) .
The IP 3 R/Ca 2+ /apoptosis connection was then further investigated by stimulating wild-type astrocytes with STS, another apoptotic stimulus that triggers cell death by disrupting the IP 3 receptor-mediated calcium homeostasis (58) (59) (60) (61) 69 ). Here we found that the treatment with STS causes a sustained increase in [Ca 2+ ] i , which is similar to that triggered by DHPG in ALS astrocytes, but to higher levels. Also in this case, the [Ca 2+ ] i rise is associated to degeneration of a significant number of cells. Interestingly, the [Ca 2+ ] i released by hSOD1 G93A -expressing or wild-type astrocytes treated with DHPG or STS, respectively, quantitatively correlated with the extent of cell death. Thus, we infer that, in both conditions, it is the persistent IP 3 R-mediated Ca 2+ release from the intracellular stores that underlies astrocyte degeneration. This finding is particularly interesting in view of previous observations indicating that IP 3 R2, the isoform predominantly (or selectively) expressed in astrocytes (70) , is up-regulated in cells from sporadic ALS patients (71) .
Fine tuning of the intracellular Ca 2+ homeostasis by the anti-apoptotic Bcl-2/Bcl-X L proteins was described to control cell death mechanisms (29, 31, 38) . Although the BH4 domain of Bcl-2 was reported to be necessary and sufficient to prevent apoptosis by regulating the efflux of calcium from the ER (35) , the role of the N-terminal BH4 domain of Bcl-X L in modulating pro-survival Ca 2+ signals was not explored. In this study, we thus investigated the impact of the BH4 domain of Bcl-X L on astrocyte Ca 2+ signaling by exploiting a biologically active BH4 peptide fused to the HIV-1 TAT protein. Consistent with previous evidence using the full-length Bcl-X L protein (36,37), we found that TAT-BH4 modulates the IP 3 R-dependent Ca 2+ release from the ER and restores spontaneous Ca 2+ oscillations in mutant SOD1-expressing astrocytes. This tight control of IP 3 Rs by the peptide prevents the DHPG-induced aberrant release of Ca 2+ from the intracellular stores and protects the cells from excitotoxic damage.
The fact that TAT-BH4 re-establishes Ca 2+ oscillations and inhibits astrocyte degeneration in a dose-dependent manner also upon STS treatment confirms the efficacy of the peptide towards IP 3 R-dependent astroglial cell death, thus establishing a correlation between the deranged mGluR5 Ca 2+ signaling and the degenerative process of hSOD1 G93A -expressing astrocytes. Further studies are clearly necessary to clarify the mechanisms by which hSOD1 G93A directly or indirectly interferes with mGluR5 signaling in astroglial cells. However, on the basis of our results, we can hypothesize that the reduction in Bcl-X L expression identified in ALS astrocytes may account, at least in part, for the loss of intracellular Ca 2+ homeostasis identified in the mutant cells. Furthermore, additional and complementary hypotheses can be formulated from the available evidence. For example, a recent study indicates that conformational changes of Bcl-2 and exposure of the pro-apoptotic BH3 domain occur at the mitochondrial membrane in mutant SOD1-expressing cells (72) . Considering that the BH3-containing pro-apoptotic members of the Bcl-2 family proteins were implied in the regulation of ER Ca 2+ signaling (73), one can postulate that the occurrence of a similar event at the ER, due to the accumulation of misfolded mutant SOD1s within astrocytes (24, 25, 66, 67) , might cause derangement of the intracellular Ca 2+ homeostasis and trigger Ca 2+ -dependent cell death. In both cases, re-introduction of Bcl-X L BH4, in the form of cell-permeable peptide, overcomes the biochemical and functional defects triggered by mutant SOD1 in astrocytes either by reinforcing the endogenous Bcl-X L or by counteracting the deleterious effects of the BH3 domain.
A crucial indication that astrocyte alterations are implicated in ALS progression in vivo came from the original observation that reducing mutant SOD1 expression within astrocytes significantly affects the late disease progression in hSOD1 G37R transgenic mice (9) . More recent evidence, using the same genetic approach, then suggested that ablation of the mutant protein specifically in astrocytes affects disease onset and early disease progression in hSOD1 G85R animals (10). Although both studies highlight the importance of astroglial cells in familial ALS, they also suggest that distinct mutations may differently influence the course of the disease. A role for hSOD1 G93A astrocytes in triggering motor neuron degeneration and ALS symptoms in vivo has been clearly demonstrated in a recent study using a cell transplantation strategy (11) . However, no information is currently available on the impact of hSOD1 G93A astroglial cells on disease progression. Since intraperitoneal injection of TAT-conjugated proteins was previously reported to allow an efficient transduction of the fusion proteins into the brain cells (56), here we investigated the impact on both gliodegeneration and disease progression of the TAT-BH4 peptide in hSOD1 G93A mice, using this route of administration. The dosage of 5 mg/kg of body weight was selected in our preclinical trial for two reasons. First, the acute treatment of mice with equivalent doses of TAT-Bcl-X L resulted protective against other neurodegenerative conditions, such as ischemic injury of the brain (74) . Second, the chronic administration of similar doses of TATconjugated proteins, on a daily basis, was reported to produce no signs of neurological impairment or systemic distress in wild-type mice, thus suggesting no obvious toxicity of the TAT protein (56) . In hSOD1 G93A mice, we found that the prolonged treatment with the peptide, starting at the presymptomatic stage of the disease, slightly delays the onset of the disease and improves both motor performance and survival of ALS transgenic mice. These effects are not accompanied by a reduction in the expression of mGluR5 in the different cell types, possibly because the peptide acts on its downstream effectors. However, they correlate with a reduction in the number of astrocytes located in proximity of motor neurons and expressing the apoptotic effector caspase-3. Noteworthy, the overall number of astroglial cells that are placed in more distant positions compared with motor neuronal somas were unaffected by the treatment. In contrast, microglial cells were moderately, but significantly, reduced, probably as a consequence of diminished astrocyte degeneration. These results correlate with the preservation of a greater number of motor neurons. Whether the effect towards motor neurons is a consequence of the maintenance of a larger number of neurosupportive astrocytes in the motor neuron microenvironment or can be partially ascribed to a direct action of the peptide on these cells remains to be elucidated. Nevertheless, comparative analyses of internalized TAT-BH4 in situ indicate that the peptide is more easily captured by astrocytes than motor neurons, suggesting that the major effect may be at the astroglial level.
In conclusion, our results indicate for the first time the BH4 domain of Bcl-X L as a novel therapeutic for ALS. Furthermore, this study points at cell-permeable peptides as an innovative class of drugs suitable for mechanistic studies and endowed with a potential for curing ALS.
MATERIALS AND METHODS
Transgenic mice and breeding
Transgenic mice expressing human SOD1
G93A
(B6SJL-TgN(SOD1-G93A)1Gur) were purchased from the Jackson Laboratories. The colonies were maintained by breeding hemizygote males to wild-type C57Bl6/SJL F1 hybrid females. Offspring were genotyped and used for subsequent studies. Animal procedures were approved by the Italian Ministry of Health.
ALS biopsy material
Autoptic tissues from sALS cases were obtained from the Department of Pathology of the Academic Medical Center (University of Amsterdam) and the Netherlands ALS Tissue Bank. Informed consent was obtained for the use of brain tissue. Tissue was acquired and used in a manner compliant with the Declaration of Helsinki. All autopsies took place within 12 h after death.
All cases were reviewed independently by two neuropathologists, and the diagnosis of ALS was confirmed according to the previously described histopathological criteria (75) .
Tissue preparation and immunohistological analysis
For mouse tissue preparation, the spine was taken and immersed in 4% buffered paraformaldehyde for 24 h; spinal cord was extracted, the lumbar tract was removed and either paraffin embedded or cryoprotected in 30% sucrose before freezing. For human tissue preparation, spinal cord was removed and 0.5-cm thick slices were taken from the cervical (C7), thoracic (T4 and T8) and lumbar (L1) levels. Slices were fixed in 10% buffered formalin and embedded in paraffin. Mouse or human spinal cords were sectioned at 5 -10 mm and used to perform different immunostaining. On selected sections, the following primary antibodies were used: GFAP (mouse monoclonal antibody, 1:50, Dako), SMI32 (mouse monoclonal antibody, 1:500, Covance), MAPs (rabbit polyclonal antibody, 1:200, Sigma), CD11b (rat monoclonal antibody, 1:500, Serotec), mGluR5 (rabbit polyclonal antibody, 1:100, MBL International Corporation); active caspase-3 (rabbit polyclonal antibody, 1:50, Cell Signalling Technology), TAT (mouse monoclonal antibody, 1:10, kindly provided by Prof. Dag Helland, University of Bergen, Norway). For active caspase-3 immunostaining, a Tyramide Amplification System Kit was used (Perkin Elmer, Inc. ). To resolve background problems with mouse primary antibody on murine tissues, a Vector w M.O.M. TM Immunodetection Kit (Vector) was used. For histopathological analysis, serial sections were either immunostained for GFAP/active caspase-3 or treated with 0.5% cresyl violet (Sigma-Aldrich) to detect motor neuron Nissl substance. GFAP/active caspase-3-positive astrocytes and motor neurons were counted for a total of nine disectors using an unbiased stereologic physical disector technique (76) .
Z-axis image stacks (z-step size: 0.5 mm) were collected to generate three-dimensional data sets of spinal cord sections on an MRC 1024 Bio-Rad confocal microscope with a 63× Plan Neofluar NA1,25 oil-immersion objective in condition of optimal iris diameter as defined by LaserSharp 2000 software.
Quantitative analysis of punctuate mGluR5, GFAP or CD11b staining was performed on confocal acquired images (1024 × 1024 pixels) of the spinal cord ventral horns from both wild-type and hSOD1 G93A animals using ImageJ software (National Institutes of Health, Bethesda, MD, http://rsb.info. nih.gov/ij/). After establishing an intensity threshold, the software calculated the percentage of area occupied by mGluR5, GFAP or CD11b staining by dividing the area of immunopositivity by the total area. To quantify the number of GFAP and CD11b immunopositive cells in the ventral horns of the lumbar spinal cord, 18 fields/mouse from three animals per each experimental condition were analyzed by ImageJ software (10).
Astrocyte cultures
Primary astrocyte cultures (.99% GFAP-positive) were prepared from the spinal cord of newborn mice (hSOD1 G93A or wild-type littermates) as previously described (25) . Once the cultures reached the confluence, they were re-plated at the optimal density either in 24-well plates or 35-mm Petri dishes containing glass coverslips and maintained in Minimal Essential Medium (MEM, Gibco) supplemented with 10% fetal bovine serum (Sigma-Aldrich).
Quantitative RT-PCR
Total RNA was extracted from animal tissues or confluent astrocytes in culture using RNeasy Mini Kit (Qiagen) according to the manufacturer's guidelines. One microgram of tissue-or astrocyte-extracted total RNA was reverse-transcribed using iScript cDNA Synthesis Kit according to the manufacturer's instructions (Bio-Rad). Two nanograms of the resulting cDNAs were analyzed by quantitative PCR using the SsoFast EvaGreen Supermix on a CFX96 Real-Time PCR Detection System (BIO-RAD). mGluR5-encoding transcripts were detected using primers 5 ′ -mGluR5-Car ( 
Pharmacological treatments in vitro
To assess the ability of TAT-BH4 to penetrate into cells, astrocytes (8 × 10 4 cells/well) were plated in 24-well plates containing glass coverslips. Cultures were treated with 10 mg/ml To test the protective efficacy of TAT-BH4, astrocytes in culture were pre-exposed to different concentrations of the peptide (0.1 and/or 0.5 mM, 30 min), washed and then treated with DHPG (100 mM, 30 min, Tocris Cookson Ltd) or STS (1 mM, 6 h, Sigma-Aldrich). After removal of DHPG, astrocytes were allowed to recover at 378C for 24 h.
Immunocytochemistry and quantitative analysis
Confluent astrocytes were fixed either in 4% buffered paraformaldehyde for 15 min at room temperature or in methanol for 10 min at 2208C. Cells were then immunostained using the following primary antibodies: Bcl-X L (rabbit polyclonal antibody, 1:50, Santa Cruz), TAT (mouse monoclonal antibody, 1:10, kindly provided by Prof. Dag Helland, University of Bergen, Norway), cytochrome c (mouse monoclonal antibody, 1:100, BD Pharmingen), SOD2 (rabbit polyclonal antibody, 1:50, Stressgen), active caspase-3 (rabbit polyclonal antibody, 1:50, Cell Signaling). For quantitative analysis of punctuate Bcl-X L staining, the total fluorescence of 15 ROI/cell (ROI: 2.09 mm × 2.09 mm) was calculated using ImageJ software (n ¼ 50 cells per each experimental condition). Cytochrome c release from mitochondria was determined by its co-localization with the mitochondrial protein SOD2 using JACoP plug-in ImageJ. An estimate of the degree of co-localization was obtained by calculating the Pearson's and Manders' coefficients (78) .
The toxic effect of DHPG or STS on cultured astrocytes was determined by double staining with the fluorescent nuclear dye Hoechst 33342 and anti-active caspase-3 immunostaining. The number of astrocytes showing condensed nuclei and activated caspase-3, 24 h after the pharmacological challenge, was counted by two independent operators in a blind manner. The number of dying astrocytes was counted in 8 -10 microscopic fields (40×) per coverslip and expressed as percentage of the total number of cells present in the field.
Pharmacological treatment in vivo
hSOD1
G93A mice were administrated daily 5 mg/kg L-TAT-BH4 peptide (GenScript) or vehicle (PBS containing 10% glycerol) intraperitoneally starting at the age of 40 days (n ¼ 14 mice for each condition). Mice were thereafter kept under daily observation and weighted twice a week. Age of disease onset was retrospectively determined as the time when mice reached the peak in the body weight. Motor performance was assessed twice a week by rotarod test starting at the age of 50 days. Briefly, animals were placed on an accelerating rod (Ugo Basile) and the time each mouse remained on the rod was recorded. The average of three independent trials per session was used for further analysis of the data. End stage was defined as the time in which animals were unable to right themselves within 30 s when placed on their side.
Statistics. Data are represented as mean + s.e.m. and statistical significance was verified using GraphPad Prism w software. Paired or unpaired 2-tailed t-test was used for comparisons between two groups; one-way or two-way analysis of variance (ANOVA) followed by Bonferroni post-hoc test was used for comparisons of multiple groups; repeated-measures two-way ANOVA was used for behavioral test; the Logrank test was used for disease onset and survival analysis.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
